Elicio Therapeutics (ELTX) Cash from Investing Activities (2020 - 2025)
Elicio Therapeutics (ELTX) reported Cash from Investing Activities of -$16000.0 for Q4 2025, up 64.44% on a YoY basis from -$9729.7 in Q4 2024, and up 64.44% quarter-over-quarter from -$45000.0 in Q4 2024.
Elicio Therapeutics (ELTX) Cash from Investing Activities (2020 - 2025) Analysis & Trends
Elicio Therapeutics has reported Cash from Investing Activities for 6 years, with the latest figure at -$16000.0 in Q4 2025.
- For the quarter ending Q4 2025, Cash from Investing Activities rose 64.44% year-over-year to -$16000.0; the trailing twelve-month figure through Dec 2025 stood at -$16000.0 (up 80.95% YoY), and the FY2025 full-year result was -$16000.0, up 80.95% from the prior year.
- Cash from Investing Activities for Q4 2025 stood at -$16000.0, up from -$45000.0 in the prior quarter.
- The five-year high for Cash from Investing Activities was $30000.0 in Q2 2023, with the low at -$559000.0 in Q2 2022.
- Historically, Cash from Investing Activities has averaged -$89846.2 across 5 years, with a median of -$42000.0 in 2024.
- Annual changes were most pronounced in 2021 — Cash from Investing Activities plunged 6000.0% — and 2024, when it soared 117.65%.
- Elicio Therapeutics' Cash from Investing Activities stood at -$36000.0 in 2021, then plunged by 163.89% to -$95000.0 in 2022, then surged by 52.63% to -$45000.0 in 2023, then changed by 0.0% to -$45000.0 in 2024, then surged by 64.44% to -$16000.0 in 2025.
- The last three Cash from Investing Activities figures came in at -$16000.0 (Q4 2025), -$45000.0 (Q4 2024), and -$42000.0 (Q2 2024), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -2.89 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | 638.50 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | - |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | -431.90 Mn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | 579,519.10 |
| 10 | Elicio Therapeutics | 270.44 Mn | 255.50 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2025 | -16,000.00 |
| Dec 31, 2024 | -45,000.00 |
| Dec 31, 2024 | -45,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Jun 30, 2024 | -42,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Mar 31, 2024 | 3,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Sep 30, 2023 | -45,000.00 |
| Jun 30, 2023 | 30,000.00 |
| Jun 30, 2023 | 30,000.00 |
| Mar 31, 2023 | -17,000.00 |
| Mar 31, 2023 | -17,000.00 |
| Dec 31, 2022 | -95,000.00 |
| Dec 31, 2022 | -95,000.00 |
| Jun 30, 2022 | -559,000.00 |
| Jun 30, 2022 | -559,000.00 |
| Dec 31, 2021 | -36,000.00 |
| Dec 31, 2021 | -36,000.00 |